SEHK:9926Biotechs
Akeso (SEHK:9926) Valuation: Assessing Pipeline Momentum After Landmark Alzheimer’s and Oncology R&D Milestones
Akeso (SEHK:9926) has just been cleared by China’s National Medical Products Administration to initiate clinical trials for AK152, its first bispecific antibody aimed at tackling Alzheimer’s Disease, and a breakthrough in the domestic biotech space.
See our latest analysis for Akeso.
While Akeso's progress on Alzheimer's and its oncology advances have kept it in the headlines, the share price has pulled back 36% over the past three months after a rapid rally earlier this year. Still, the...